s-1
Showing 1 - 25 of 99
Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)
Recruiting
- Gastric Cancer
- AK104
- +3 more
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
May 7, 2023
Immunotherapy Gastrict Cancer Trial (Tislelizumab, apatinib, oxaliplatin)
Not yet recruiting
- Immunotherapy Gastrict Cancer
- Tislelizumab
- +3 more
- (no location specified)
Jan 17, 2023
Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)
Not yet recruiting
- Gastric Cancer
- Disitamab Vedotin
- +3 more
- (no location specified)
Nov 17, 2022
Capecitabine Versus S-1 as Adjuvant Therapy in Biliary Tract
Recruiting
- Biliary Tract Neoplasms
- +3 more
- S-1
- Capecitabine
-
Shanghai, ChinaHuashan hospital
Aug 16, 2022
Advanced Gastroesophageal Adenocarcinoma Trial in Beijing (RC48-ADC, S-1)
Recruiting
- Advanced Gastroesophageal Adenocarcinoma
- RC48-ADC
- S-1
-
Beijing, China
- +2 more
Sep 14, 2022
Gastric Cancer Trial in Beijing (S-1, Trastuzumab, Oxaliplatin)
Completed
- Gastric Cancer
- S-1
- +3 more
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences
Aug 14, 2022
Locally Advanced or Metastatic Pancreatic Cancer Trial (S-1)
Completed
- Locally Advanced or Metastatic Pancreatic Cancer
- S-1
- (no location specified)
Nov 9, 2021
Advanced or Metastatic NSCLC Trial in Worldwide (TAS-114, S-1)
Completed
- Advanced or Metastatic Non-small Cell Lung Cancer
- TAS-114
- S-1
-
Loma Linda, California
- +29 more
Nov 24, 2021
Resected Pancreatic Cancer, Pancreatic Cancer, Adjuvant Chemo Trial in Linkou, Tainan, Taipei (S-1)
Terminated
- Resected Pancreatic Cancer
- +2 more
- S-1
-
Linkou, Taiwan
- +3 more
Nov 22, 2021
Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers Trial in Taipei (Oxaliplatin, Albumin-Bound Paclitaxel
Completed
- Gastric Cancer in Situ
- +2 more
- Oxaliplatin
- +3 more
-
Taipei, TaiwanTaiwan Cooperative Oncology Group, National Health Research Inst
Apr 5, 2022
Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Tislelizumab
- +4 more
-
Wuhan, Hubei, China
- +2 more
Jan 16, 2023
Metastatic Solid Tumor, NSCLC, Gastric Cancer Trial (RO7496353, Atezolizumab, Capecitabine)
Not yet recruiting
- Metastatic Solid Tumor
- +3 more
- RO7496353
- +7 more
- (no location specified)
May 22, 2023
Adenocarcinoma,Stomach, Adenocarcinoma, Esophagogastric Junction Trial in München (S-1)
Completed
- Adenocarcinoma,Stomach
- Adenocarcinoma, Esophagogastric Junction
- S-1
-
München, Bayern, GermanyKlinikum der Universität München, Campus Großhadern
Apr 28, 2021
Metastatic Colorectal Cancer Trial in Fuzhou (S-1, Irinotecan, Bevacizumab)
Withdrawn
- Metastatic Colorectal Cancer
- S-1
- +2 more
-
Fuzhou, Fujian, ChinaRongbo Lin
Mar 4, 2021
Nasopharyngeal Carcinoma Trial in Shanghai (S-1)
Completed
- Nasopharyngeal Carcinoma
- S-1
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 10, 2021
Colorectal Adenocarcinoma Trial in Fuzhou (S-1, Bevacizumab, Capecitabine)
Withdrawn
- Colorectal Adenocarcinoma
- S-1
- +2 more
-
Fuzhou, Fujian, ChinaRongbo Lin
Mar 4, 2021
Hepatocellular Carcinoma Trial in Hangzhou (Sorafenib, S-1, Oxaliplatin)
Withdrawn
- Hepatocellular Carcinoma
- Sorafenib
- +2 more
-
Hangzhou, ChinaFirst affiliated hospital, Zhejiang University
Feb 12, 2021
Gastric Cancer, Neoadjuvant Therapy Trial in Beijing (radiation, drug, procedure)
Recruiting
- Gastric Cancer
- Neoadjuvant Therapy
- SIB-IMRT
- +3 more
-
Beijing, ChinaDepartment of Radiation Oncology, Cancer Hospital, Chinese Acade
Jan 20, 2022
Esophageal Cancer, Chemoradiotherapy, Nimotuzumab Trial in Beijing (Radiotherapy, Nimotuzumab, S-1)
Recruiting
- Esophageal Cancer
- +3 more
- Radiotherapy
- +2 more
-
Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/Nationa
Oct 21, 2021
Gastric Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (Camrelizumab, Pyrotinib, Capecitabine)
Not yet recruiting
- Gastric Neoplasms
- Gastroesophageal Junction Adenocarcinoma
- Camrelizumab
- +5 more
-
Shanghai, China270 Dongan Road, Fudan University Shanghai Cancer Center
Oct 27, 2021
Gastric Cancer, Perioperative, Sintilimab Trial in Tianjin (Sintilimab, S-1, Oxaliplatin)
Recruiting
- Gastric Cancer
- +2 more
- Sintilimab
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Aug 25, 2021
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Japan, Korea, Republic of, Taiwan
Completed
- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Ramucirumab
- +4 more
-
Akashi, Japan
- +33 more
Feb 23, 2022
Esophageal Cancer, Chemoradiation Trial in Hangzhou (Radiotherapy 54 Gy, Radiotherapy 60 Gy, S-1)
Completed
- Esophageal Cancer
- Chemoradiation
- Radiotherapy 54 Gy
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 13, 2020
Esophageal Squamous Cell Carcinoma Trial in Guangzhou (SMART, DDP, S-1)
Completed
- Esophageal Squamous Cell Carcinoma
- SMART
- +2 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Sep 2, 2020